HRP20110716T1 - Aril dikarboksamidi - Google Patents
Aril dikarboksamidi Download PDFInfo
- Publication number
- HRP20110716T1 HRP20110716T1 HR20110716T HRP20110716T HRP20110716T1 HR P20110716 T1 HRP20110716 T1 HR P20110716T1 HR 20110716 T HR20110716 T HR 20110716T HR P20110716 T HRP20110716 T HR P20110716T HR P20110716 T1 HRP20110716 T1 HR P20110716T1
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- unsubstituted
- amino
- alkyl
- carbonyl
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title claims abstract 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 5
- 239000001257 hydrogen Substances 0.000 claims abstract 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000005418 aryl aryl group Chemical group 0.000 claims abstract 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- -1 cyano, hydroxy, mercapto Chemical class 0.000 claims 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 239000005711 Benzoic acid Substances 0.000 claims 6
- 235000010233 benzoic acid Nutrition 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 5
- 229960004889 salicylic acid Drugs 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000006733 (C6-C15) alkyl group Chemical group 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- FTJHKZQHQDKPFJ-UHFFFAOYSA-N (carbamoylamino)carbamic acid Chemical compound NC(=O)NNC(O)=O FTJHKZQHQDKPFJ-UHFFFAOYSA-N 0.000 claims 2
- 125000002999 4-(trifluoromethyl)benzoyl group Chemical group FC(C1=CC=C(C(=O)*)C=C1)(F)F 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- NPFIUHQJRZGQPG-UHFFFAOYSA-N 2-[4-[[(2-phenoxyacetyl)-[[2-[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl]amino]methyl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1CN(C(=O)COC=1C=CC=CC=1)CC1=CSC(C=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 NPFIUHQJRZGQPG-UHFFFAOYSA-N 0.000 claims 1
- CXBFVXKWGMJURV-UHFFFAOYSA-N 2-[4-[[[2-(dimethylamino)acetyl]-[[2-[4-(4-phenylbutylcarbamoyl)phenyl]-1,3-thiazol-4-yl]methyl]amino]methyl]phenoxy]acetic acid Chemical compound C=1C=C(OCC(O)=O)C=CC=1CN(C(=O)CN(C)C)CC(N=1)=CSC=1C(C=C1)=CC=C1C(=O)NCCCCC1=CC=CC=C1 CXBFVXKWGMJURV-UHFFFAOYSA-N 0.000 claims 1
- CKYRYIQTDPFWJP-XQNSMLJCSA-N 2-[4-[[[2-[4-(4-phenylbutylcarbamoyl)phenyl]-1,3-thiazol-4-yl]methyl-[(e)-3-phenylprop-2-enoyl]amino]methyl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1CN(C(=O)\C=C\C=1C=CC=CC=1)CC1=CSC(C=2C=CC(=CC=2)C(=O)NCCCCC=2C=CC=CC=2)=N1 CKYRYIQTDPFWJP-XQNSMLJCSA-N 0.000 claims 1
- FCAHBLZPXKOXRN-UHFFFAOYSA-N 2-[4-[[[2-[4-(4-phenylbutylcarbamoyl)phenyl]-1,3-thiazol-4-yl]methyl-[4-(trifluoromethyl)benzoyl]amino]methyl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1CN(C(=O)C=1C=CC(=CC=1)C(F)(F)F)CC1=CSC(C=2C=CC(=CC=2)C(=O)NCCCCC=2C=CC=CC=2)=N1 FCAHBLZPXKOXRN-UHFFFAOYSA-N 0.000 claims 1
- XEKRVDVNLZIACS-UHFFFAOYSA-N 2-[4-[[[2-[4-(octylcarbamoyl)phenyl]-1,3-thiazol-4-yl]methyl-(3-phenylpropanoyl)amino]methyl]phenoxy]acetic acid Chemical compound C1=CC(C(=O)NCCCCCCCC)=CC=C1C1=NC(CN(CC=2C=CC(OCC(O)=O)=CC=2)C(=O)CCC=2C=CC=CC=2)=CS1 XEKRVDVNLZIACS-UHFFFAOYSA-N 0.000 claims 1
- FLAZSTIQEPUNAY-UHFFFAOYSA-N 2-[4-[[[2-[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl-[4-(trifluoromethyl)benzoyl]amino]methyl]phenoxy]acetic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C1=CC=C(C=2SC=C(CN(CC=3C=CC(OCC(O)=O)=CC=3)C(=O)C=3C=CC(=CC=3)C(F)(F)F)N=2)C=C1 FLAZSTIQEPUNAY-UHFFFAOYSA-N 0.000 claims 1
- HXHLJIMPJZGDJR-UHFFFAOYSA-N 2-[4-[[[2-[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl-[4-(trifluoromethyl)benzoyl]amino]methyl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1CN(C(=O)C=1C=CC(=CC=1)C(F)(F)F)CC1=CSC(C=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 HXHLJIMPJZGDJR-UHFFFAOYSA-N 0.000 claims 1
- YIFJGICTMLQRNV-UHFFFAOYSA-N 2-[4-[[[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]methyl-[4-(trifluoromethyl)benzoyl]amino]methyl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1CN(C(=O)C=1C=CC(=CC=1)C(F)(F)F)CC1=CC=C(C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C=C1 YIFJGICTMLQRNV-UHFFFAOYSA-N 0.000 claims 1
- APFLCNKRXAFAEF-UHFFFAOYSA-N 2-hydroxy-4-[[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]methyl-[4-(trifluoromethyl)benzoyl]amino]benzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C(C=C1)=CC=C1CN(C=1C=C(O)C(C(O)=O)=CC=1)C(=O)C1=CC=C(C(F)(F)F)C=C1 APFLCNKRXAFAEF-UHFFFAOYSA-N 0.000 claims 1
- MLLJUCAPOORHDS-UHFFFAOYSA-N 2-hydroxy-5-[(2-phenoxyacetyl)-[[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]methyl]amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)COC=2C=CC=CC=2)=C1 MLLJUCAPOORHDS-UHFFFAOYSA-N 0.000 claims 1
- RIEGSJMQHPNZED-UHFFFAOYSA-N 2-hydroxy-5-[3-methylbut-2-enoyl-[[2-[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl]amino]benzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C1=CC=C(C=2SC=C(CN(C(=O)C=C(C)C)C=3C=C(C(O)=CC=3)C(O)=O)N=2)C=C1 RIEGSJMQHPNZED-UHFFFAOYSA-N 0.000 claims 1
- VHKIBEQZLOZWSK-UHFFFAOYSA-N 2-hydroxy-5-[[2-[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl-[4-(trifluoromethyl)benzoyl]amino]benzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C1=CC=C(C=2SC=C(CN(C(=O)C=3C=CC(=CC=3)C(F)(F)F)C=3C=C(C(O)=CC=3)C(O)=O)N=2)C=C1 VHKIBEQZLOZWSK-UHFFFAOYSA-N 0.000 claims 1
- OOEIVGDKMDSJFG-UHFFFAOYSA-N 2-hydroxy-5-[[2-[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl-(3-phenylpropanoyl)amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2N=C(SC=2)C=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)CCC=2C=CC=CC=2)=C1 OOEIVGDKMDSJFG-UHFFFAOYSA-N 0.000 claims 1
- LFFPQQXFGADOTH-UHFFFAOYSA-N 2-hydroxy-5-[[2-[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl-[4-(trifluoromethyl)benzoyl]amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2N=C(SC=2)C=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 LFFPQQXFGADOTH-UHFFFAOYSA-N 0.000 claims 1
- XDZRTNYGBPNNII-UHFFFAOYSA-N 2-hydroxy-5-[[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]methyl-(3-phenylpropanoyl)amino]benzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C(C=C1)=CC=C1CN(C=1C=C(C(O)=CC=1)C(O)=O)C(=O)CCC1=CC=CC=C1 XDZRTNYGBPNNII-UHFFFAOYSA-N 0.000 claims 1
- LNEYSWBYZUJJPR-UHFFFAOYSA-N 2-hydroxy-5-[[4-[(4-phenoxyphenyl)methylcarbamoyl]-1,3-thiazol-2-yl]methyl-(3-phenylpropanoyl)amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2SC=C(N=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)CCC=2C=CC=CC=2)=C1 LNEYSWBYZUJJPR-UHFFFAOYSA-N 0.000 claims 1
- RPUZJMCKNCDCCL-UHFFFAOYSA-N 2-hydroxy-5-[[4-[(4-phenoxyphenyl)methylcarbamoyl]-1,3-thiazol-2-yl]methyl-[4-(trifluoromethyl)benzoyl]amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2SC=C(N=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 RPUZJMCKNCDCCL-UHFFFAOYSA-N 0.000 claims 1
- CISLRUUVLWUCHA-UHFFFAOYSA-N 2-hydroxy-5-[[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]methyl-(3-phenylpropanoyl)amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)CCC=2C=CC=CC=2)=C1 CISLRUUVLWUCHA-UHFFFAOYSA-N 0.000 claims 1
- DZDSZFDDLDHYAH-PXLXIMEGSA-N 2-hydroxy-5-[[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]methyl-[(e)-3-phenylprop-2-enoyl]amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)\C=C\C=2C=CC=CC=2)=C1 DZDSZFDDLDHYAH-PXLXIMEGSA-N 0.000 claims 1
- WWVMZQLVQAQTTO-UHFFFAOYSA-N 2-hydroxy-5-[[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]methyl-[4-(trifluoromethyl)benzoyl]amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 WWVMZQLVQAQTTO-UHFFFAOYSA-N 0.000 claims 1
- WFCDPJZDVJLUAU-UHFFFAOYSA-N 2-hydroxy-5-[[[4-(octylcarbamoyl)phenyl]methyl-(2-phenoxyacetyl)amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)NCCCCCCCC)=CC=C1CN(C(=O)COC=1C=CC=CC=1)CC1=CC=C(O)C(C(O)=O)=C1 WFCDPJZDVJLUAU-UHFFFAOYSA-N 0.000 claims 1
- ONJDTUVILNQEGM-UHFFFAOYSA-N 2-hydroxy-5-[[[4-(octylcarbamoyl)phenyl]methyl-[4-(trifluoromethyl)benzoyl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)NCCCCCCCC)=CC=C1CN(C(=O)C=1C=CC(=CC=1)C(F)(F)F)CC1=CC=C(O)C(C(O)=O)=C1 ONJDTUVILNQEGM-UHFFFAOYSA-N 0.000 claims 1
- UKVJDXJZZBQSJY-UHFFFAOYSA-N 2-hydroxy-5-[[[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]methyl-(2-phenoxyacetyl)amino]methyl]benzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C(C=C1)=CC=C1CN(C(=O)COC=1C=CC=CC=1)CC1=CC=C(O)C(C(O)=O)=C1 UKVJDXJZZBQSJY-UHFFFAOYSA-N 0.000 claims 1
- KUWSGDRFKSTVEE-UHFFFAOYSA-N 2-hydroxy-5-[[[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]methyl-[4-(trifluoromethyl)benzoyl]amino]methyl]benzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C(C=C1)=CC=C1CN(C(=O)C=1C=CC(=CC=1)C(F)(F)F)CC1=CC=C(O)C(C(O)=O)=C1 KUWSGDRFKSTVEE-UHFFFAOYSA-N 0.000 claims 1
- WBHZNAQHMWPELK-UHFFFAOYSA-N 4-[3-cyclopentylpropanoyl-[[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C(C=C1)=CC=C1CN(C=1C=C(O)C(C(O)=O)=CC=1)C(=O)CCC1CCCC1 WBHZNAQHMWPELK-UHFFFAOYSA-N 0.000 claims 1
- OSFADAFKTPSSCV-UHFFFAOYSA-N 5-[(4-cyanobenzoyl)-[[2-[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C1=CC=C(C=2SC=C(CN(C(=O)C=3C=CC(=CC=3)C#N)C=3C=C(C(O)=CC=3)C(O)=O)N=2)C=C1 OSFADAFKTPSSCV-UHFFFAOYSA-N 0.000 claims 1
- CUNBWODFBJIRTC-UHFFFAOYSA-N 5-[(4-cyanobenzoyl)-[[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)C=2C=CC(=CC=2)C#N)=C1 CUNBWODFBJIRTC-UHFFFAOYSA-N 0.000 claims 1
- GXIYEKTVXBVWPW-UHFFFAOYSA-N 5-[(6-chloropyridine-3-carbonyl)-[[2-[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C1=CC=C(C=2SC=C(CN(C(=O)C=3C=NC(Cl)=CC=3)C=3C=C(C(O)=CC=3)C(O)=O)N=2)C=C1 GXIYEKTVXBVWPW-UHFFFAOYSA-N 0.000 claims 1
- WUTVNBPTVYUJJL-UHFFFAOYSA-N 5-[3-cyclopentylpropanoyl-[[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)CCC2CCCC2)=C1 WUTVNBPTVYUJJL-UHFFFAOYSA-N 0.000 claims 1
- GUJCLAIIBPUHNV-UHFFFAOYSA-N 5-[[3-cyclopentylpropanoyl-[[4-[(4-pentylphenyl)methylcarbamoyl]phenyl]methyl]amino]methyl]-2-hydroxybenzoic acid Chemical compound C1=CC(CCCCC)=CC=C1CNC(=O)C(C=C1)=CC=C1CN(C(=O)CCC1CCCC1)CC1=CC=C(O)C(C(O)=O)=C1 GUJCLAIIBPUHNV-UHFFFAOYSA-N 0.000 claims 1
- VUGVHWIYDOTFHG-UHFFFAOYSA-N 5-[acetyl-[[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]methyl]amino]-2-hydroxybenzoic acid Chemical compound C=1C=C(O)C(C(O)=O)=CC=1N(C(=O)C)CC(C=C1)=CC=C1C(=O)NCC(C=C1)=CC=C1OC1=CC=CC=C1 VUGVHWIYDOTFHG-UHFFFAOYSA-N 0.000 claims 1
- SJBHRGLXGLBOBY-UHFFFAOYSA-N 5-[benzoyl-[[2-[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]-1,3-thiazol-4-yl]methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2N=C(SC=2)C=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)C=2C=CC=CC=2)=C1 SJBHRGLXGLBOBY-UHFFFAOYSA-N 0.000 claims 1
- ANCVOGMIGBIFOS-UHFFFAOYSA-N 5-[benzoyl-[[4-[(4-phenoxyphenyl)methylcarbamoyl]-1,3-thiazol-2-yl]methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2SC=C(N=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)C=2C=CC=CC=2)=C1 ANCVOGMIGBIFOS-UHFFFAOYSA-N 0.000 claims 1
- OQIRIDMPHWDPFH-UHFFFAOYSA-N 5-[cyclohexanecarbonyl-[[4-[(4-phenoxyphenyl)methylcarbamoyl]phenyl]methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C=CC(=CC=2)C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)C2CCCCC2)=C1 OQIRIDMPHWDPFH-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 235000021229 appetite regulation Nutrition 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Upotreba aril dikarboksamida prema formuli (I) : kao i njegovih geometrijskih izomera, njegovih optički aktivnih oblika kao enantiomera, as, diastereomera i njegovih racematnih oblika, naznačena time daA is aminokarbonilna skupina prema formuli -CO-NHR6 pri čemu R6 je supstituiran ili nesupstituiran C6-C15 alkil, supstituiran ili nesupstituiran C2-C15-alkenil, supstituiran ili nesupstituiran C2-C15-alkinil, supstituiran ili nesupstituiran 3-8 člani cikloalkil, supstituiran ili nesupstituiran C1-C6 alkil-(3-8 člani) cikloalkil, supstituiran ili nesupstituiran fenil, supstituiran ili nesupstituiran C1-C12 alkil fenil, supstituiran ili nesupstituiran C2-C6 alkenil fenil, supstituiran ili nesupstituiran C2-C6 alkinil fenil; Cy je supstituiran ili nesupstituiran aril, supstituiran ili nesupstituiran heteroaril, supstituiran ili nesupstituiran aril-heteroaril, supstituiran ili nesupstituiran heteroaril- aril, supstituiran ili nesupstituiran aril-aril, supstituiran ili nesupstituiran cikloalkil ili supstituirana ili nesupstituirana heterociklička skupina; n je bilo 0 ili 1; R1 i R2 su nezavisno jedan od drugoga odabrani iz skupine koja sadrži vodik ili supstituiran ili nesupstituiran C1-C6-alkil; R3 je odabran iz skupine koja sadrži supstituiran ili nesupstituiran C1-C6-alkil, supstituiran ili nesupstituiran C2-C6-alkenil, supstituiran ili nesupstituiran C2-C6-alkinil, supstituiran ili nesupstituiran C1-C6-alkoksi, supstituiran ili nesupstituiran C1-C6-alkil amin, supstituiran ili nesupstituiran C1-C6-alkil alkoksi, supstituiran ili nesupstituiran aril, supstituiran ili nesupstituiran heteroaril, supstituiran ili nesupstituiran zasićeni ili nezasićeni 3-8-člani cikloalkil, supstituiran ili nesupstituiran 3-8-člani heterocikloalkil, supstituiran ili nesupstituiran C1-C6-alkil aril, supstituiran ili nesupstituiran C1-C6-alkil heteroaril, supstituiran ili nesupstituiran C2-C6-alkenil aril, supstituiran ili nesupstituiran C2-C6-alkenil heteroaril, supstituiran ili nesupstituiran C2-C6-alkinil aril, supstituiran ili nesupstituiran C2-C6-alkinil heteroaril, supstituiran ili nesupstituiran C1-C6-alkil cikloalkil, supstituiran ili nesupstituiran C1-C6-alkil heterocikloalkil, supstituiran ili nesupstituiran C2-C6-alkenil cikloalkil, supstituiran ili nesupstituiran C2-C6-alkenil heterocikloalkil, supstituiran ili nesupstituiran C2-C6-alkinil cikloalkil, supstituiran ili nesupstituiran C2-C6-alkinil heterocikloalkil; R4 i R5 su nezavisno jedan od drugoga odabrani iz skupine koja sadrži H, hidroksi, supstituiran ili nesupstituiran C1-C6 alkil, karboksi, supstituiran ili nesupstituiran C1-C6 alkoksi, supstituiran ili nesupstituiran C1-C3 alkil karboksi, supstituiran ili nesupstituiran C2-C3 alkenil karboksi, supstituiran ili nesupstituiran C2-C3 alkinil karboksi, amino ili R4 i R5 mogu tvoriti nezasićeni ili zasićeni heterociklički prsten, pri čemu barem jedan od R4 ili R5 nije vodik ili C1-C6 alkil; pri čemu gore navedene skupine, kada su supstituirane, su supstitu
Claims (13)
1. Upotreba aril dikarboksamida prema formuli (I) :
[image]
kao i njegovih geometrijskih izomera, njegovih optički aktivnih oblika kao enantiomera, as, diastereomera i njegovih racematnih oblika, naznačena time da
A is aminokarbonilna skupina prema formuli -CO-NHR6 pri čemu R6 je supstituiran ili nesupstituiran C6-C15 alkil, supstituiran ili nesupstituiran C2-C15-alkenil, supstituiran ili nesupstituiran C2-C15-alkinil, supstituiran ili nesupstituiran 3-8 člani cikloalkil, supstituiran ili nesupstituiran C1-C6 alkil-(3-8 člani) cikloalkil, supstituiran ili nesupstituiran fenil, supstituiran ili nesupstituiran C1-C12 alkil fenil, supstituiran ili nesupstituiran C2-C6 alkenil fenil, supstituiran ili nesupstituiran C2-C6 alkinil fenil;
Cy je supstituiran ili nesupstituiran aril, supstituiran ili nesupstituiran heteroaril, supstituiran ili nesupstituiran aril-heteroaril, supstituiran ili nesupstituiran heteroaril- aril, supstituiran ili nesupstituiran aril-aril, supstituiran ili nesupstituiran cikloalkil ili supstituirana ili nesupstituirana heterociklička skupina;
n je bilo 0 ili 1;
R1 i R2 su nezavisno jedan od drugoga odabrani iz skupine koja sadrži vodik ili supstituiran ili nesupstituiran C1-C6-alkil;
R3 je odabran iz skupine koja sadrži supstituiran ili nesupstituiran C1-C6-alkil, supstituiran ili nesupstituiran C2-C6-alkenil, supstituiran ili nesupstituiran C2-C6-alkinil, supstituiran ili nesupstituiran C1-C6-alkoksi, supstituiran ili nesupstituiran C1-C6-alkil amin, supstituiran ili nesupstituiran C1-C6-alkil alkoksi, supstituiran ili nesupstituiran aril, supstituiran ili nesupstituiran heteroaril, supstituiran ili nesupstituiran zasićeni ili nezasićeni 3-8-člani cikloalkil, supstituiran ili nesupstituiran 3-8-člani heterocikloalkil, supstituiran ili nesupstituiran C1-C6-alkil aril, supstituiran ili nesupstituiran C1-C6-alkil heteroaril, supstituiran ili nesupstituiran C2-C6-alkenil aril, supstituiran ili nesupstituiran C2-C6-alkenil heteroaril, supstituiran ili nesupstituiran C2-C6-alkinil aril, supstituiran ili nesupstituiran C2-C6-alkinil heteroaril, supstituiran ili nesupstituiran C1-C6-alkil cikloalkil, supstituiran ili nesupstituiran C1-C6-alkil heterocikloalkil, supstituiran ili nesupstituiran C2-C6-alkenil cikloalkil, supstituiran ili nesupstituiran C2-C6-alkenil heterocikloalkil, supstituiran ili nesupstituiran C2-C6-alkinil cikloalkil, supstituiran ili nesupstituiran C2-C6-alkinil heterocikloalkil;
R4 i R5 su nezavisno jedan od drugoga odabrani iz skupine koja sadrži H, hidroksi, supstituiran ili nesupstituiran C1-C6 alkil, karboksi, supstituiran ili nesupstituiran C1-C6 alkoksi, supstituiran ili nesupstituiran C1-C3 alkil karboksi, supstituiran ili nesupstituiran C2-C3 alkenil karboksi, supstituiran ili nesupstituiran C2-C3 alkinil karboksi, amino ili R4 i R5 mogu tvoriti nezasićeni ili zasićeni heterociklički prsten, pri čemu barem jedan od R4 ili R5 nije vodik ili C1-C6 alkil;
pri čemu gore navedene skupine, kada su supstituirane, su supstituirane sa od 1 do 5 supstituenata odabranih iz skupine koja sadrži C1-C6-alkil, C2-C6-alkenil, C2-C6-alkinil, cikloalkil, heterocikloalkil, C1-C6-alkil aril, C1-C6-alkil heteroaril, C1-C6-alkil cikloalkil, C1-C6-alkil heterocikloalkil, amino, amonijak, acil, aciloksi, acilamino, aminokarbonil, alkoksikarbonil, ureido, karbamat, aril, heteroaril, sulfinil, sulfonil, alkoksi, sulfanil, halogen, karboksi, trihalometil, cijano, hidroksi, merkapto i nitro, ili gdje su susjedni supstituenti podvrgnuti zatvaranju prstena;
za dobivanje lijeka za liječenje i/ili prevenciju metaboličkih poremećaja posredovanih otpornošću na inzulin ili hiperglikemijom, uključujući dijabetes, neadekvatnu toleranciju glukoze, hiperlipidemiju, hipertrigliceridemiju, hiperkolesterolemiju, pretilost, sindrom policističnih jajnika (PCOS).
2. Upotreba aril dikarboksamida prema zahtjevu 1 naznačena time da je za dobivanje lijeka za liječenje i/ili prevenciju dijabetesa tipa II, pretilosti ili za regulaciju apetita.
3. Upotreba prema zahtjevu 1 ili 2, naznačena time da R1 i R2 su svaki H.
4. Upotreba prema bilo kojem od zahtjeva 1 do 3, naznačena time da Cy je odabran iz skupine koja sadrži fenil, tiazolil, fenil-tiazolil, tiazolil-fenil.
5. Upotreba prema bilo kojem od zahtjeva 1 do 4, naznačena time da A je skupina prema formuli -CO-NHR6 pri čemu R6 je C6-C15 alkil, C2-C15 -alkenil, C2-C15 -alkinil, 3-8 člani cikloalkil, C1-C6 alkil-(3-8 člani) cikloalkil, fenil, C1-C12 alkil fenil, C2-C6-alkenil fenil, C2-C6-alkinil fenil.
6. Aril dikarboksamid prema bilo kojoj od formula (Ia), (Ib) ili (Ic) :
[image]
naznačen time da
A je aminokarbonilna skupina prema formuli -CO-NHR6 pri čemu R6 je supstituiran ili nesupstituiran C6-C15 alkil, supstituiran ili nesupstituiran C2-C15-alkenil, supstituiran ili nesupstituiran C2-C15-alkinil, supstituiran ili nesupstituiran 3-8 člani cikloalkil, supstituiran ili nesupstituiran C1-C6 alkil-(3-8 člani) cikloalkil, supstituiran ili nesupstituiran fenil, supstituiran ili nesupstituiran C1-C12 alkil fenil, supstituiran ili nesupstituiran C2-C6-alkenil fenil, supstituiran ili nesupstituiran C2-C6- alkinil fenil;
Cy je supstituiran ili nesupstituiran aril, supstituiran ili nesupstituiran heteroaril, supstituiran ili nesupstituiran aril-heteroaril, supstituiran ili nesupstituiran heteroaril- aril, supstituiran ili nesupstituiran aril-aril, supstituiran ili nesupstituiran cikloalkil ili supstituirana ili nesupstituirana heterociklička skupina;
n je bilo 0 ili 1;
R1 i R2 su nezavisno jedan od drugoga odabrani iz skupine koja sadrži vodik ili supstituiran ili nesupstituiran C1-C6-alkil;
R3 je odabran iz skupine koja sadrži supstituiran ili nesupstituiran C1-C6-alkil, supstituiran ili nesupstituiran C2-C6-alkenil, supstituiran ili nesupstituiran C2-C6- alkinil, supstituiran ili nesupstituiran C1-C6-alkoksi, supstituiran ili nesupstituiran C1-C6-alkil amin, supstituiran ili nesupstituiran C1-C6-alkil alkoksi, supstituiran ili nesupstituiran aril, supstituiran ili nesupstituiran heteroaril, supstituiran ili nesupstituiran zasićeni ili nezasićeni 3-8-člani cikloalkil, supstituiran ili nesupstituiran 3-8- člani heterocikloalkil, acilnu skupinu, supstituiran ili nesupstituiran C1-C6-alkil aril, supstituiran ili nesupstituiran C1-C6-alkil heteroaril, supstituiran ili nesupstituiran C2-C6-alkenil aril, supstituiran ili nesupstituiran C2-C6-alkenil heteroaril, supstituiran ili nesupstituiran C2-C6-alkinil aril, supstituiran ili nesupstituiran C2-C6-alkinil heteroaril, supstituiran ili nesupstituiran C1-C6-alkil cikloalkil, supstituiran ili nesupstituiran C1-C6-alkil heterocikloalkil, supstituiran ili nesupstituiran C2-C6-alkenil cikloalkil, supstituiran ili nesupstituiran C2-C6-alkenil heterocikloalkil, supstituiran ili nesupstituiran C2-C6-alkinil cikloalkil, supstituiran ili nesupstituiran C2-C6-alkinil heterocikloalkil;
pri čemu gore navedene skupine, kada su supstituirane, su supstituirane sa od 1 do 5 supstituenata odabranih iz skupine koja sadrži C1-C6-alkil, C2-C6-alkenil, C2-C6-alkinil, cikloalkil, heterocikloalkil, C1-C6-alkil aril, C1-C6-alkil heteroaril, C1-C6-alkil cikloalkil, C1-C6-alkil heterocikloalkil, amino, amonijak, acil, aciloksi, acilamino, aminokarbonil, alkoksikarbonil, ureido, karbamat, aril, heteroaril, sulfinil, sulfonil, alkoksi, sulfanil, halogen, karboksi, trihalometil, cijano, hidroksi, merkapto i nitro, ili gdje su susjedni supstituenti podvrgnuti zatvaranju prstena.
7. Aril dikarboksamid prema zahtjevu 6, naznačen time da R1 i R2 su svaki H.
8. Aril dikarboksamid prema zahtjevu 6 ili 7, naznačen time da Cy je odabran iz skupine koja sadrži fenil, tiazolil, fenil-tiazolil, tiazolil-fenil.
9. Aril dikarboksamid prema bilo kojem od zahtjeva 6 do 8, naznačen time da R6 je odabran iz skupine koja sadrži C8-C12 alkil, C1-C4 alkil fenil koji može biti supstituiran sa C1-C8 alkilom ili fenoksi.
10. Aril dikarboksamid prema bilo kojem od prethodnih zahtjeva naznačen time da je odabran iz skupine koja sadrži:
5-[(3-ciklopentilpropanoil)(4-{[(4-fenoksibenzil)amino]karbonil}benzil)amino]-2-hidroksibenzojevu kiselinu,
[4-({{[2-(4-{[(4-pentilbenzil)amino]karbonil}fenil)-l,3-tiazol-4-il]metil}-[(2E)-3-fenilprop-2-enoil]aminometil)fenoksi]octenu kiselinu,
5-[(3-ciklopentilpropanoil)(4-[(4-pentilbenzil)amino]karbonil}benzil)amino]-2-hidroksibenzojevu kiselinu,
2-hidroksi-5-(4-{[(4-pentilbenzil)amino]karbonil}benzil){4-(trifluorometil)-benzoil]amino}benzojevu kiselinu,
2-hidroksi-5-[[(4-{[(4-fenoksibenzil)amino]karbonil}-l,3-tiazol-2-il)metil](3-fenilpropanoil)amino]benzojevu kiselinu,
5-{benzoil[(4-{[(4-fenoksibenzil)amino]karbonil}-1,3-tiazol-2-il)metil]-amino}-2-hidroksibenzojevu kiselinu,
2-hidroksi-5-{[(4-{[(4-fenoksibenzil)amino]karbonil}-l,3--tiazol-2-il)metil][4-(trifluorometil)benzoil]amino}benzojevu kiselinu,
5-[(cikloheksilkarbonil)(4-{[(4-fenoksibenzil)amino]karbonil}benzil)amino]-2-hidroksibenzojevu kiselinu,
2-hidroksi-5-[(4-{[(4-fenoksibenzil)amino]karbonil}benzil)(3-fenilpropanoil)-amino]benzojevu kiselinu,
5-[benzoil(4-[(4-fenoksibenzil)amino]karbonil}benzil)amino]-2-hidroksibenzojevu kiselinu,
5-[acetil(4-{[(4-fenoksibenzil)amino]karbonil}benzil)amino]-2-hidroksibenzojevu kiselinu,
5-[(4-cijanobenzoil)(4-{[(4-fenoksibenzil)amino]karbonil}benzil)amino]-2-hidroksibenzojevu kiselinu,
2-hidroksi-5-[(fenoksiacetil)(4-{[(4-fenoksibenzil)amino]karbonil}benzil)-amino]-benzojevu kiselinu,
2-hidroksi-5-{(4-{[(4-fenoksibenzil)amino]karbonil}benzil)[4-(trifluorometil)-benzoil]amino}benzojevu kiselinu,
2-hidroksi-5-{(4-{[(4-fenoksibenzil)amino]karbonil}benzil)[(2E)-3-fenilprop-2-enoil]amino}benzojevu kiselinu,
5-[(N,N-dimetilglicil)(4-{[4-fenoksibenzil)amino]karbonil}benzil)amino]-2-hidroksibenzojevu kiselinu,
2-hidroksi-5-[(3-metilbut-2-enoil)(4-{(4-fenoksibenzil)amino]karbonil}benzil)-amino]benzojevu kiselinu,
2-hidroksi-5-{[{4-[(oktilamino)karbonil]benzil}(fenoksiacetil)amino]metil}-benzojevu kiselinu,
2-hidroksi-5-({{4-[(oktilamino)karbonil]benzil}[4-(trifluorometil)benzoil]-amino}metil)benzojevu kiselinu,
2-hidroksi-5-({{4-[(oktilamino)karbonil]benzil}[(2E)-h-fenilprop-2-enoil]-amino}metil)benzojevu kiselinu,
5-{[(3-ciklopentilpropanoil)(4-{[(4-pentilbenzil)amino]karbonil}benzil)-amino]metil}-2-hidroksibenzojevu kiselinu,
2-hidroksi-5-{[(4-{[(4-pentilbenzil)amino]karbonil}benzil)(fenoksiacetil)-amino]metil}benzojevu kiselinu,
2-hidroksi-5-({(4-{[(4-pentilbenzil)amino]karbonil}benzil)[4-(trifluorometil)-benzoil]amino}metil)benzojevu kiselinu,
2-hidroksi-5-[(3-metilbut-2-enoil)(4-{[(4-pentilbenzil)amino]karbonil}-benzil)amino]metil}benzojevu kiselinu,
5-{[(3-ciklopentilpropanoil)(4-{[(4-fenilbutil)amino]karbonilbenzil)-amino]metil}-2-hidroksibenzojevu kiselinu,
2-hidroksi-5-({[(4-{[(4-pentilbenzil)amino]karbonil}-l,3-tiazol-2-il)metil][(2£)-3-fenilprop-2-enoil]amino}metil)benzojevu kiselinu,
[4-({(4-{[(4-fenoksibenzil)amino]karbonil}benzil)[4-(trifluorometil)benzoil]-amino}metil)fenoksi]octenu kiselinu,
2-hidroksi-5-[(4-{[(4-pentilbenzil)amino]karbonil}benzil)(3-fenilpropanoil)-amino]benzojevu kiselinu,
4-[(3-ciklopentilpropanoil)(4-{[(4-pentilbenzil)amino]karbonil}benzil)amino]-2-hidroksibenzojevu kiselinu,
2-hidroksi-4-{(4-{[(4-pentilbenzil)amino]karbonil}benzil)[4-(trifluorometil)-benzoil]amino}benzojevu kiselinu,
2-hidroksi-5-[{[2-(4-{[(4-pentilbenzil)amino]karbonilfenil)-1,3-tiazol-4-il]metil}(fenoksiacetil)amino]benzojevu kiselinu,
2-hidroksi-5-{{[2-(4-{[(4-pentilbenzil)amino]karbonil}fenil)-1,3-tiazol-4-il]metil}[4-(trifluorometil)benzoil]amino}benzojevu kiselinu,
5-([(6-kloropiridin-3-il)karbonil]{[2-(4-[[(4-pentilbenzil)amino]karbonil}-fenil)-l,3-tiazol~4-il]metil}amino)-2-hidroksibenzojevu kiselinu,
5-((4-cijanobenzoil){[2-(4-{[(4-pentilbenzil)amino]karbonil}fenil)-1,3-tiazol-4-il]metil}amino)-2-hidroksibenzojevu kiselinu,
2-hidroksi-5-((3-metilbut-2-enoil){[2-(4-{[(4-pentilbenzil)amino]karbonil}-fenil)-1,3-tiazol-4-il]metil}amino)benzojevu kiselinu,
5-((3-ciklopentilpropanoil){[2-(4-{[(4-fenoksiben2il)amino]cart)onil}fenil)-l,3-tiazol-4-il]metil}amino)-2-hidroksibenzojevu kiselinu,
2-hidroksi-5-{{[2-(4-{[(4-fenoksibenzil)amino]karbonil}fenil)-l,3-tiazol-4-il]metil}[4-(trifluorometil)benzoil]amino}benzojevu kiselinu,
2-hidroksi-5-[{[2-(4-{[(4-fenoksibenzil)amino]karbonil}fenil)-1,3-tiazol-4-il]metil}(3-fenilpropanoil)amino]benzojevu kiselinu,
5-(benzoil{[2-(4-{[(4-fenoksibenzil)amino]karbonil}fenil)-1,3-tiazol-4-il]metil}amino)-2-hidroksibenzojevu kiselinu,
[4-({{[2-(4-{[(4-pentilbenzil)amino]karbonil}fenil)-l,3-tiazol-4-il]metil}[4-(trifluorometil)benzoil]amino}metil)fenoksi]octenu kiselinu,
(4-{[{[2-(4-{[(4-pentilbenzil)amino]karbonil}fenil)-1,3-tiazol-4-il]metil}(3-fenilpropanoil)amino]metil}fenoksi)octenu kiselinu,
[4-({{[2-(4-{[(4-fenilbutil)amino]karbonil}fenil)-l,3-tiazol-4-il]metil}[4-(trifluorometil)benzoil]amino}metil)fenoksi]octenu kiselinu,
(4-{[{[2-(4-{[(4-fenilbutil)amino]karbonil}fenil)-l,3-tiazol-4-il]metil}(3-fenilpropanoil)amino]metil}fenoksi)octenu kiselinu,
[4-({{[2-(4-{[(4-fenilbutil)amino]karbonil}fenil)-1,3-tiazol-4-il]metil}[(2E)-3-fenilprop-2-enoil]amino}metil)fenoksi]octenu kiselinu,
{4-[((N,N-dimetilglicil){[2-(4-{[(4-fenilbutil)amino]karbonil}fenil)-l,3-tiazol-4-il]metil}amino)metil]fenoksi}octenu kiselinu,
{4-[((cikloheksilkarbonil){[2-(4-{[(4-fenilbutil)amino]karbonil}fenil)-l,tiazol-4-il]metil}amino)metil]fenoksi}octenu kiselinu,
{4-[((fenoksiacetil){[2-(4-{[(4-fenoksibenzil)amino]karbonil}fenil)-l,3-tiazol-4-il]metil}amino)metil]fenoksi}octenu kiselinu,
[4-({{[2-(4-{[(4-fenoksibenzil)amino]karbonil}fenil)-1,3-tiazol-4-il]metil}[4-(trifluorometil)benzoil]amino}metil)fenoksi]octenu kiselinu,
(4-{[{[2-(4-{[(4-fenoksibenzil)amino]karbonil}fenil)-1,3-tiazol-4-il]metil}(3-fenilpropanoil)amino]metil}fenoksi)octenu kiselinu,
{4-[((cikloheksilkarbonil){[2-(4-{[(4-fenoksibenzil)amino]karbonil}fenil)-1,3-tiazol-4-il]amino)metil]fenoksi}octenu kiselinu,
[4-({[(2-{4-[(oktilamino)karbonil]fenil}-153-tiazol-4-il)metil],[4-(trifluorometil)benzoil]amino}metil)fenoksi]octenu kiselinu,
(4-{[[(2-{4-[(oktilamino)karbonil]fenil}-l,3-tiazol-4-il)metil](3-fenilpropanoil)amino]metil}fenoksi)octenu kiselinu.
11. Aril dikarboksamid prema bilo kojem od zahtjeva 6 do 10 naznačen time da je za upotrebu kao lijek.
12. Farmaceutski pripravak naznačen time da sadrži barem jadan aril dikarboksamid prema bilo kojem od zahtjeva 6 do 10 i njegov farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
13. Postupak dobivanja aril dikarboksamida prema bilo kojem od zahtjeva 6 do 10, naznačen time da sadrži korak uklanjanja zaštite i/ili transformacije od:
[image]
pri čemu R1, R2, R3, R4, R5, n i Cy su kako je gore definirano, FG je A ili odlazna skupina i R4', R5' su nezavisno jedan od drugoga zaštićeni ili ne-zaštićeni oblik R4 i R5.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03102236 | 2003-07-21 | ||
US51782403P | 2003-11-06 | 2003-11-06 | |
PCT/EP2004/051558 WO2005011685A1 (en) | 2003-07-21 | 2004-07-20 | Aryl dicarboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110716T1 true HRP20110716T1 (hr) | 2011-11-30 |
Family
ID=34117529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110716T HRP20110716T1 (hr) | 2003-07-21 | 2011-10-05 | Aril dikarboksamidi |
Country Status (4)
Country | Link |
---|---|
CY (1) | CY1112175T1 (hr) |
HR (1) | HRP20110716T1 (hr) |
IL (1) | IL173196A0 (hr) |
NO (1) | NO20060815L (hr) |
-
2006
- 2006-01-17 IL IL173196A patent/IL173196A0/en unknown
- 2006-02-20 NO NO20060815A patent/NO20060815L/no not_active Application Discontinuation
-
2011
- 2011-10-05 HR HR20110716T patent/HRP20110716T1/hr unknown
- 2011-12-29 CY CY20111101289T patent/CY1112175T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL173196A0 (en) | 2006-06-11 |
NO20060815L (no) | 2006-02-20 |
CY1112175T1 (el) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2461551C2 (ru) | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль | |
JP2010519181A5 (hr) | ||
JP2009513563A5 (hr) | ||
AU766193B2 (en) | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | |
HRP20160827T1 (hr) | Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe | |
JP2010520195A5 (hr) | ||
JP2013530240A5 (hr) | ||
HRP20150395T1 (hr) | 2-aril-propionske kiseline i derivati i njihovi farmaceutski pripravci | |
HRP20211331T1 (hr) | Inhibitor površinskog antigena hepatitis b virusa | |
JP2006077019A5 (hr) | ||
RU2006137272A (ru) | Производные 2-фенилпропионовой кислоты и содержащие их фармацевтические композиции | |
RU2008142834A (ru) | Модуляция церамидкиназы | |
JP2008516986A5 (hr) | ||
JP2004534035A5 (hr) | ||
JP2004532187A5 (hr) | ||
HRP20181086T1 (hr) | Antagonisti trpm8 | |
RU2001111023A (ru) | Новые производные n-(иминометил)аминов, их получение, их использование в качестве лекарственных средств и содержащие их фармацевтические композиции | |
NZ603198A (en) | Novel hydroxamic acid derivative | |
PE20080061A1 (es) | Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 | |
JP2009529059A5 (hr) | ||
RU2006101053A (ru) | Производные бензамида или соль указанного производного | |
RU2009102516A (ru) | Ингибиторы протеинтирозинфосфатазы человека и способы их использования | |
CA2558135A1 (en) | Aqueous composition comprising thiazole derivative | |
RU2009144113A (ru) | Ингибиторы фермента диацилглицерин о-ацилтрансферазы типа 1 | |
JP2004523582A5 (hr) |